Tatyana Dubnikov Sharon

Biochemistry, Genetics and Molecular Biology · Life Sciences

4h-index76citations15works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Amyloidosis: Diagnosis, Treatment, Outcomes(9), Parathyroid Disorders and Treatments(6), Chronic Myeloid Leukemia Treatments(4), Dermatological and Skeletal Disorders(4), Multiple Myeloma Research and Treatments(3)

Publications15 total

Supplementary Table 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2025Open Access
Supplementary Figures S1-S7 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2025Open Access
Supplementary Data 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2025Open Access
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma
Blood Advances·2024· 10 citedOpen Access
Management of Atopy with Dupilumab and Omalizumab in CADINS Disease
Journal of Clinical Immunology·2024· 9 citedOpen Access
Early lymphocyte collection for <scp>anti‐CD19 CART</scp> production improves T‐cell fitness in patients with relapsed/refractory diffuse large B‐cell lymphoma
British Journal of Haematology·2023· 20 citedOpen Access
Data from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2023· 1 citedOpen Access
Supplementary Figures S1-S7 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2023Open Access
Supplementary Table 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2023Open Access
Data from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2023Open Access
Supplementary Data 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2023Open Access
Supplementary Data 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2023Open Access
Supplementary Figures S1-S7 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2023Open Access
Supplementary Table 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2023Open Access
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
Clinical Cancer Research·2022· 36 cited

Frequent Co-authors

Polina Stepensky(15), Shlomit Kfir‐Erenfeld(14), Nathalie Asherie(14), Sigal Grisariu(14), Batia Avni(14), Miri Assayag(14), Eyal Lebel(14), Moshe E. Gatt(14), Eran Zimran(13), Marjorie Pick(13), Yaël C. Cohen(13), Irit Avivi(13), Cyrille J. Cohen(13), Adir Shaulov(12), Neta Goldschmidt(1), Vladimir Vainstein(1), Shlomo Elias(1), Rivka Alexander‐Shani(1), Nomi Bessig(1), Alaa Shehadeh(1)